Evaluating RAS(ON) Inhibitors for Gastrointestinal Solid Tumors

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This platform study aims to assess the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of novel RAS(ON) inhibitors in combination with standard care or other novel agents for patients with RAS-mutated gastrointestinal cancers. It includes multiple subprotocols targeting colorectal cancer and pancreatic ductal adenocarcinoma, allowing for a flexible approach to treatment combinations. Patients will be enrolled based on specific RAS mutations and treatment history, with the goal of determining the recommended phase 2 dose and schedule for these therapies.

Why it matters

Who can join: the full rules

Inclusion Criteria:

All Patients (unless otherwise noted):

* ≥ 18 years of age
* ECOG PS is 0 to 1
* Adequate organ function as outlined by the study
* Pathologically or cytologically documented pancreatic carcinoma or poorly differentiated pancreatic carcinoma with metastatic disease or RAS-mutated, histologically or cytologically confirmed colorectal adenocarcinoma with documented unresectable or metastatic disease (Subprotocol A, B, C and G)
* Presence of RAS G12D mutation (Subprotocol D, E, F, G)

Exclusion Criteria:

All Patients:

* Primary central nervous system (CNS) tumors
* Impaired gastrointestinal (GI) function that may significantly alter the absorption of RMC drugs
* Major surgery within 28 days of first dose

Other inclusion/exclusion criteria may apply.

Where it's running

• Ironwood Cancer and Research Centers
  Chandler, Arizona, United States Recruiting
• Mayo Clinic Hospital
  Phoenix, Arizona, United States Recruiting
• HonorHealth Research Institute
  Scottsdale, Arizona, United States Recruiting
• UC San Diego Moores Cancer Center
  La Jolla, California, United States Recruiting
• Cedars-Sinai Cancer at Cedars-Sinai Medical Center
  Los Angeles, California, United States Recruiting
• UCLA Hematology/Oncology- Santa Monica
  Los Angeles, California, United States Recruiting

Study contacts

• Study coordinator: Revolution Medicines
• Email: medinfo@revmed.com
• Phone: 1-844-2-REVMED

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• ABBV-253 in adults with advanced solid tumors

  This study tests ABBV-253 to see if it is safe, how it affects the cancer, and how the drug moves in the body for adults with advanced solid tumors.

  Recruiting at 3 sites Phase 1 AbbVie · Grand Rapids, Michigan and 2 other locations · NCT07807956

• Urine test to help spot colorectal cancer and polyps

  This study tests a urine-based 3-metabolite biosensor to see if it can detect colorectal cancer and precancerous polyps in adults in Ghana, Tanzania, and South Africa.

  Recruiting Memorial Sloan Kettering Cancer Center · New York, New York and 3 other locations · NCT07649057

• IBI3028 in advanced solid tumors

  This phase 1 study tests IBI3028 in adults with unresectable or metastatic solid tumors to see if it is safe and how patients tolerate it.

  Recruiting Phase 1 Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD. · Tianjin, Tianjin Municipality · NCT07589205

• Atebimetinib plus gemcitabine and nab‑paclitaxel as first‑line treatment for metastatic pancreatic cancer

  This trial will test whether adding the MAPK pathway drug atebimetinib to gemcitabine and nab‑paclitaxel helps people with newly diagnosed metastatic pancreatic ductal adenocarcinoma live longer.

  Recruiting at 76 sites Phase 3 Immuneering Corporation · Huntsville, Alabama and 75 other locations · NCT07562152

• Telisotuzumab adizutecan with FOLFOX versus standard care in first-line metastatic pancreatic cancer

  This study tests whether adding telisotuzumab adizutecan to FOLFOX helps adults with unresectable, metastatic pancreatic cancer compare to standard treatment.

  Recruiting at 22 sites Phase 2/3 AbbVie · New Haven, Connecticut and 21 other locations · NCT07490301

• PET scan using [18F]FPyQCP to image fibroblast activation protein in several cancers

  This test tries a new PET imaging tracer, [18F]FPyQCP, to see if it helps detect colorectal, gastric, pancreatic ductal adenocarcinoma, invasive lobular breast, and epithelial ovarian cancers in adults.

  Recruiting Phase 1/2 Blue Earth Diagnostics · New York, New York and 1 other locations · NCT07432633

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.